Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform
Biotricity Inc. (OTCQB:BTCY) and B-Secur have announced a strategic partnership to develop an advanced device-neutral platform for integrated heart monitoring. The collaboration combines B-Secur's FDA-cleared HeartKey® algorithms and analytics with Biotricity's diagnostic solutions to enhance Ambulatory Cardiac Monitoring capabilities.
The partnership aims to address critical healthcare challenges, including the fact that 90% of U.S. adults are at risk of developing cardiovascular disease (CVD), an expected shortage of up to 124,000 physicians by 2034, and CVD-related costs projected to triple to $1.8 trillion by 2050. The solution focuses on early detection and intervention, which can reduce heart attack and stroke risk by over 80%.
Biotricity Inc. (OTCQB:BTCY) e B-Secur hanno annunciato una partnership strategica per sviluppare una piattaforma avanzata e neutrale rispetto ai dispositivi per il monitoraggio integrato del cuore. La collaborazione combina gli algoritmi e le analisi HeartKey® approvati dalla FDA di B-Secur con le soluzioni diagnostiche di Biotricity per migliorare le capacità di Monitoraggio Cardiaco Ambulatoriale.
La partnership mira a affrontare sfide sanitarie critiche, tra cui il fatto che il 90% degli adulti negli Stati Uniti è a rischio di sviluppare malattie cardiovascolari (CVD), una prevista carenza di fino a 124.000 medici entro il 2034, e i costi correlati alla CVD che si prevede triplicheranno a 1,8 trilioni di dollari entro il 2050. La soluzione si concentra sulla rilevazione precoce e sull'intervento, che possono ridurre il rischio di infarto e ictus di oltre 80%.
Biotricity Inc. (OTCQB:BTCY) y B-Secur han anunciado una asociación estratégica para desarrollar una plataforma avanzada e independiente del dispositivo para el monitoreo cardíaco integrado. La colaboración combina los algoritmos y análisis HeartKey® aprobados por la FDA de B-Secur con las soluciones de diagnóstico de Biotricity para mejorar las capacidades de Monitoreo Cardíaco Ambulatorio.
La asociación tiene como objetivo abordar desafíos críticos en el cuidado de la salud, incluido el hecho de que el 90% de los adultos en EE. UU. está en riesgo de desarrollar enfermedades cardiovasculares (CVD), una escasez proyectada de hasta 124,000 médicos para 2034, y los costos relacionados con la CVD que se prevé que se tripliquen a 1.8 billones de dólares para 2050. La solución se centra en la detección e intervención temprana, lo que puede reducir el riesgo de infarto y accidente cerebrovascular en más de 80%.
비오트리시티 주식회사 (OTCQB:BTCY)와 B-Secur는 통합 심장 모니터링을 위한 고급 장치 중립 플랫폼 개발을 위한 전략적 파트너십을 발표했습니다. 이 협력은 B-Secur의 FDA 승인을 받은 HeartKey® 알고리즘과 분석을 비오트리시티의 진단 솔루션과 결합하여 외래 심장 모니터링 능력을 향상시킵니다.
이 파트너십은 미국 성인의 90%가 심혈관 질환(CVD) 발생 위험에 처해 있다는 사실, 2034년까지 최대 124,000명의 의사 부족이 예상된다는 점, CVD 관련 비용이 2050년까지 1.8조 달러로 세 배 증가할 것으로 예상된다는 점 등 중요한 건강 관리 문제를 해결하는 것을 목표로 합니다. 이 솔루션은 조기 발견과 개입에 집중하여 심장마비와 뇌졸중 위험을 80% 이상 줄일 수 있습니다.
Biotricity Inc. (OTCQB:BTCY) et B-Secur ont annoncé un partenariat stratégique pour développer une plateforme avancée, neutre en matière de dispositifs, pour le monitoring intégré du cœur. La collaboration combine les algorithmes et analyses HeartKey® approuvés par la FDA de B-Secur avec les solutions de diagnostic de Biotricity afin d'améliorer les capacités de monitoring cardiaque ambulatoire.
Le partenariat vise à répondre à des défis critiques en matière de santé, y compris le fait que 90 % des adultes américains sont à risque de développer des maladies cardiovasculaires (CVD), une pénurie prévue allant jusqu'à 124 000 médecins d'ici 2034, et les coûts liés à la CVD qui devraient tripler pour atteindre 1,8 trillion de dollars d'ici 2050. La solution se concentre sur la détection et l'intervention précoces, ce qui peut réduire le risque de crise cardiaque et d'accident vasculaire cérébral de plus de 80 %.
Biotricity Inc. (OTCQB:BTCY) und B-Secur haben eine strategische Partnerschaft angekündigt, um eine fortschrittliche, geräteunabhängige Plattform für integrierte Herzüberwachung zu entwickeln. Die Zusammenarbeit kombiniert die von der FDA zugelassenen HeartKey®-Algorithmen und Analysen von B-Secur mit den diagnostischen Lösungen von Biotricity, um die Fähigkeiten des ambulanten Herzmonitorings zu verbessern.
Die Partnerschaft zielt darauf ab, kritische gesundheitliche Herausforderungen anzugehen, einschließlich der Tatsache, dass 90 % der US-Erwachsenen gefährdet sind, Herz-Kreislauf-Erkrankungen (CVD) zu entwickeln, einer voraussichtlichen Engpass von bis zu 124.000 Ärzten bis 2034 und den prognostizierten CVD-bezogenen Kosten, die bis 2050 auf 1,8 Billionen Dollar steigen sollen. Die Lösung konzentriert sich auf die frühzeitige Erkennung und Intervention, die das Risiko von Herzinfarkten und Schlaganfällen um mehr als 80 % reduzieren kann.
- Partnership combines FDA-cleared HeartKey® technology with Biotricity's diagnostic solutions
- Addresses growing market with 90% of U.S. adults at risk of CVD
- Early detection capability can reduce heart attack and stroke risk by over 80%
- Operating in a market facing severe physician shortage (124,000 by 2034)
- Cardiovascular disease costs expected to triple to $1.8 trillion by 2050
By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and Independent Diagnostic Testing Facilities with enhanced capabilities for Ambulatory Cardiac Monitoring and ambulatory devices.
"This partnership underscores the need for robust cardiac monitoring solutions in a rapidly evolving healthcare landscape," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "By working with B-Secur, we aim to address critical gaps in cardiac care delivery, improving accessibility and efficiency for healthcare providers and patients alike."
With
"We are at a pivotal moment in cardiac care," said Tyeler Dean, VP of Medical at B-Secur. "Early detection and timely intervention can reduce the risk of heart attack and stroke by over
"HeartKey® bridges this gap, providing accurate and actionable insights that help healthcare professionals deliver timely, personalized care. Our partnership with Biotricity represents an important step toward advancing the accessibility and precision of cardiac monitoring solutions, overcoming resource constraints, and ensuring better patient outcomes."
About B-Secur
B-Secur is an advanced biosensing technology company on a mission to set a new level of care in health monitoring through development of both on-device and cloud applications, driving preventative and proactive fitness and health management. B-Secur's signal processing provides medical-grade ECG data for faster, more confident diagnosis, treatment, and management. B-Secur is ISO 13485:2016 certified.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biotricity-and-b-secur-partner-to-launch-the-most-comprehensive-device-neutral-ambulatory-cardiac-monitoring-platform-302351943.html
SOURCE Biotricity
FAQ
What is the impact of Biotricity's (BTCY) partnership with B-Secur on cardiac monitoring?
How much can early detection reduce heart attack risk for BTCY platform users?
What market challenges is BTCY addressing with this new partnership?
What technology is being integrated into BTCY's cardiac monitoring platform?
